Turning Point Therapeutics, Inc., was incorporated in Delaware on October 8, 2013 under the name TP Therapeutics, Inc. In November 2018, they changed their name to Turning Point Therapeutics, Inc. The company is a clinical-stage biopharmaceutical company that designs and develops novel small molecule, targeted tumor therapies to address critical limitations of existing therapies and improve the lives of patients. They internally develop and wholly own a pipeline of next-generation tyrosine kinase inhibitors (TKIs) for a variety of cancer genetic factors in TKI primitive and TKI pretreated patients. The general challenge of intrinsic and acquired treatment resistance often limits the response rate and durability of existing therapies. One of these challenges is the emergence of pre-solvent mutations, which are a common cause of acquired resistance to currently approved ROS1, TRK and ALK kinase therapies. The company has developed a large cycle platform capable of designing proprietary small compact TKIs with rigid three-dimensional structures that may have higher precision and affinity than other kinase inhibitors. 

TPTX(Delisted)